Condition (MeSH)
Drug-Related Side Effects and Adverse Reactions
ClinicalTrials.gov lists 1,088 trials for Drug-Related Side Effects and Adverse Reactions or a narrower condition beneath it. Children's Oncology Group has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
443 of the 1,088 trials are tagged with Drug-Related Side Effects and Adverse Reactions itself; the rest are tagged with a narrower condition beneath it.
When did Drug-Related Side Effects and Adverse Reactions trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 91
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 48 |
| 2025 | 59 |
| 2024 | 68 |
| 2023 | 73 |
| 2022 | 76 |
| 2021 | 91 |
| 2020 | 68 |
| 2019 | 58 |
| 2018 | 47 |
| 2017 | 58 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 58 trials starting in 2026 and about 55 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 86 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 590 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Drug-Related Side Effects and Adverse Reactions trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 57 |
| Phase 1/2 | 33 |
| Phase 2 | 134 |
| Phase 2/3 | 17 |
| Phase 3 | 77 |
| Phase 4 | 69 |
| Not applicable | 298 |
| Observational | 402 |
| Expanded access | 1 |
How many Drug-Related Side Effects and Adverse Reactions trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 58 |
| Recruiting | 136 |
| Enrolling by invitation | 8 |
| Active, not recruiting | 34 |
| Available | 1 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Drug-Related Side Effects and Adverse Reactions trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 8 |
| VA Office of Research and Development | 7 |
Which drugs are being tested for Drug-Related Side Effects and Adverse Reactions? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 20 |
| Amifostine | 19 |
| Dexrazoxane | 10 |
| (nab)-paclitaxel | 9 |
| TRASTUZUMAB | 8 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 22 |
| Doxorubicine | 20 |
| Radiation Therapy | 16 |
| Etoposid | 13 |
| Filgrastime (G-CSF) | 12 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Drug-Related Side Effects and Adverse Reactions trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sepsis | 923 | 6 |
| Acute kidney injury | 787 | 2 |
| Infection w/ gr 3-4 neut- blood | 288 | 1 |
| New arrhythmia | 287 | 1 |
| Acute lung injury/ Acute respiratory distress syndrome | 238 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Drug-Related Side Effects and Adverse Reactions? (2,046)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Plasma endogenous metabolome as superior biomarkers for adverse effects compared to drug and its metabolites. | Future oncology (London, England) | 2026 | Yes |
| Pharmacogenomics in the prediction of adverse effects of cardiovascular drugs: the PGx-CardioDrug project. | Croatian medical journal | 2026 | Yes |
| Breaking barriers: feasibility of a cluster randomised trial evaluating an instrument for identifying and ameliorating adverse drug reactions. | BMJ open | 2026 | Yes |
| Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®). | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation | 2025 | Yes |
| Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial. | The oncologist | 2025 | Yes |
Showing 5 of 2,046 publications.
Sub-conditions in MeSH (14)
MeSH descendants one level down with at least one trial, most trials first.
+4 more sub-conditions
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.